Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Alcon acquires global rights to Zyclorin from Sirion

Alcon acquires global rights to Zyclorin from Sirion

30th March 2010

Alcon has completed the acquisition of global rights to a new topical ophthalmic immunomodulator and immunosuppressive agent from Sirion Therapeutics.

The company has finalised the deal for Zyclorin after receiving approval from regulators, with the deal extending to all worldwide territories other than Latin America.

Zyclorin is currently the subject of clinical investigation to establish its potential for treating dry eye and other ocular surface diseases.

This agreement has also seen Alcon take over the US rights to the pain-relieving topical ophthalmic corticosteroid Durezol, while it is considering an additional move to purchase the antiviral treatment Zirgan.

Stuart Raetzman, vice-president of global marketing for Alcon, said: “This acquisition reinforces our ability to drive growth in the near-term with the acquisition of Durezol and add products to our long-term research pipeline with Zyclorin.”

Last month, the company published its financial results for 2009, during which it recorded a 6.3 per cent year-on-year increase in organic sales.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.